NCT02143804View on ClinicalTrials.gov

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Bladder CancerHigh GradeNon Muscle Invasive
Interventions
BIOLOGICAL

oncolytic adenovirus expressing GMCSF

Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.

Trial Locations (1)

85032

BCG Oncology, Phoenix

Sponsors

Lead Sponsor

CG Oncology, Inc.
All Listed Sponsors
lead

CG Oncology, Inc.

INDUSTRY